NCT04054206View on ClinicalTrials.gov

Relative Bioavailability of MN-166 (Ibudilast) in Extended Release Tablet vs. Intermediate-release Capsule in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

June 24, 2019

Primary Completion Date

July 17, 2019

Study Completion Date

May 31, 2020

Conditions
Healthy Volunteers
Interventions
DRUG

MN-166

MN-166 (ibudilast) is an orally available small molecule drug currently being investigated for human treatment in multiple sclerosis, amyotrophic lateral sclerosis, glioblastoma, and alcohol and drug use disorders.

Trial Locations (1)

92845

Collaborative Neuroscience Network, Garden Grove

Sponsors

Lead Sponsor

MediciNova
All Listed Sponsors
lead

MediciNova

INDUSTRY